AR132992A1 - Agonistas de trem2 - Google Patents
Agonistas de trem2Info
- Publication number
- AR132992A1 AR132992A1 ARP240101553A ARP240101553A AR132992A1 AR 132992 A1 AR132992 A1 AR 132992A1 AR P240101553 A ARP240101553 A AR P240101553A AR P240101553 A ARP240101553 A AR P240101553A AR 132992 A1 AR132992 A1 AR 132992A1
- Authority
- AR
- Argentina
- Prior art keywords
- trem2
- agonists
- compounds
- diseases
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención proporciona compuestos que tienen la fórmula general (1) en donde A¹, A², X¹, X², R¹, R², R³, R⁴ y R⁷ son como se describen en la presente, composiciones que incluyen los compuestos, procesos para elaborar los compuestos y métodos para usar los compuestos en el tratamiento o la prevención de enfermedades que están asociadas con TREM2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23179957 | 2023-06-19 | ||
| EP23211237 | 2023-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132992A1 true AR132992A1 (es) | 2025-08-13 |
Family
ID=91621082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101553A AR132992A1 (es) | 2023-06-19 | 2024-06-18 | Agonistas de trem2 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP4727934A1 (es) |
| JP (1) | JP2026521750A (es) |
| KR (1) | KR20260023587A (es) |
| CN (1) | CN121335893A (es) |
| AR (1) | AR132992A1 (es) |
| AU (1) | AU2024312352A1 (es) |
| CL (1) | CL2025004002A1 (es) |
| CO (1) | CO2025018165A2 (es) |
| CR (1) | CR20250537A (es) |
| IL (1) | IL324897A (es) |
| MX (1) | MX2025015264A (es) |
| PE (1) | PE20260310A1 (es) |
| TW (1) | TW202515878A (es) |
| WO (1) | WO2024260929A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2025206254A1 (en) | 2024-01-04 | 2026-06-11 | Muna Therapeutics Aps | Trem2 modulators |
| IL328677A (en) | 2024-01-04 | 2026-07-01 | Muna Therapeutics Aps | 2-Azatidinyl-7-methyl-8-oxo-6-(trifluoromethyl)-8,7-dihydropyrimido[4,5-D]pyrimidine derivatives as TREM2 modulators for the treatment of neurodegenerative diseases |
| WO2026077861A1 (en) * | 2024-10-07 | 2026-04-16 | F. Hoffmann-La Roche Ag | Trem2 agonists |
| WO2026115009A1 (en) * | 2024-11-29 | 2026-06-04 | F. Hoffmann-La Roche Ag | Trem2 agonists |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8318732B2 (en) * | 2008-07-02 | 2012-11-27 | Avexa Limited | Compounds having antiviral properties |
| EP4430029A4 (en) * | 2021-11-09 | 2025-09-10 | Vigil Neuroscience Inc | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL AGONISTS 2 AND METHODS OF USE |
-
2024
- 2024-06-17 PE PE2025003141A patent/PE20260310A1/es unknown
- 2024-06-17 KR KR1020267001588A patent/KR20260023587A/ko active Pending
- 2024-06-17 JP JP2025574086A patent/JP2026521750A/ja active Pending
- 2024-06-17 IL IL324897A patent/IL324897A/en unknown
- 2024-06-17 CN CN202480040255.2A patent/CN121335893A/zh active Pending
- 2024-06-17 EP EP24735173.7A patent/EP4727934A1/en active Pending
- 2024-06-17 WO PCT/EP2024/066833 patent/WO2024260929A1/en not_active Ceased
- 2024-06-17 CR CR20250537A patent/CR20250537A/es unknown
- 2024-06-17 AU AU2024312352A patent/AU2024312352A1/en active Pending
- 2024-06-18 AR ARP240101553A patent/AR132992A1/es unknown
- 2024-06-18 TW TW113122490A patent/TW202515878A/zh unknown
-
2025
- 2025-12-16 MX MX2025015264A patent/MX2025015264A/es unknown
- 2025-12-18 CL CL2025004002A patent/CL2025004002A1/es unknown
- 2025-12-18 CO CONC2025/0018165A patent/CO2025018165A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2025004002A1 (es) | 2026-04-06 |
| WO2024260929A1 (en) | 2024-12-26 |
| CO2025018165A2 (es) | 2026-01-23 |
| EP4727934A1 (en) | 2026-04-22 |
| MX2025015264A (es) | 2026-02-03 |
| TW202515878A (zh) | 2025-04-16 |
| JP2026521750A (ja) | 2026-07-01 |
| IL324897A (en) | 2026-01-01 |
| AU2024312352A1 (en) | 2025-12-11 |
| PE20260310A1 (es) | 2026-02-11 |
| CN121335893A (zh) | 2026-01-13 |
| CR20250537A (es) | 2026-01-19 |
| KR20260023587A (ko) | 2026-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| AR126854A1 (es) | Compuestos macrocíclicos para el tratamiento de cáncer | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| PH12021551065A1 (en) | Fused ring compounds | |
| PH12021500014A1 (en) | Fused ring compounds | |
| CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| MX2018007774A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| UY37656A (es) | Compuestos que inhiben la proteína mcl-1 | |
| BR112019000247A2 (pt) | derivados de 1,3-di-hidróxi-fenila úteis como imunomoduladores | |
| CU24564B1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
| CL2021000292A1 (es) | Benzimidazoles sustituidos como inhibidores de pad4. | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| BR112022005627A2 (pt) | Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica e uso de um composto | |
| CO2025018165A2 (es) | Agonistas de trem2 | |
| CL2022000019A1 (es) | Nuevos compuestos heterocíclicos | |
| CL2020001107A1 (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3. | |
| MX2024007360A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| MX2023009059A (es) | Antagonistas de gpr84 y usos de estos. | |
| PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| UY39881A (es) | “COMPUESTOS N-ACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS” | |
| PY1986693A (es) | Compuestos herbicidas | |
| AR134046A1 (es) | Inhibidores de cbl-b y métodos de uso de los mismos | |
| AR134419A1 (es) | Compuestos que inhiben la quinasa tipo polo 4 | |
| BR112021017710A2 (pt) | Composto, composição farmacêutica, método de tratamento |